In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Dermira (NASDAQ: DERM), with a price target of $20. The company’s shares opened today at $9.43, close to its 52-week low of $6.98.
Chen wrote:
“DERM is a leading dermatology company with pipeline advancements that could drive upwards earnings revisions and the stock higher. Valuation Summary We use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $20. The Disclosure Section may be found on pages 3 – 4.Valuation We use a blend of DCF and multiples (EV/EBITDA) analysis to reach our 12-month price target of $20.”
According to TipRanks.com, Chen has 0 stars on 0-5 star ranking scale with an average return of -3.6% and a 42.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Melinta Therapeutics Inc, and Aclaris Therapeutics Inc.
Dermira has an analyst consensus of Hold, with a price target consensus of $15.
See today’s analyst top recommended stocks >>
Based on Dermira’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $23.93 million. In comparison, last year the company had a GAAP net loss of $38.57 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Dermira, Inc. is a biopharmaceutical company, which engages in the provision of biotech ingenuity to medical dermatology. It focuses on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis, and acne.
